NEW YORK, Feb. 5, 2018 /PRNewswire/ -- WallStEquities.com strives to bring the best free research to the investment community.Today we are offering reports on ACAD, AKAO, ACHN, and ACOR which can be accessed for free by signing up to www.wallstequities.com/registration. WallStEquities.com revisits the Biotechnology space, which includes companies that are engaged in the
San Diego, California headquartered ACADIA Pharmaceuticals Inc.'s stock finished last Friday's session 4.30% lower at $28.96. A total volume of 1.06 million shares was traded. The Company's shares are trading below their 50-day moving average by 0.98%. Additionally, shares of ACADIA Pharma, which focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders, have a Relative Strength Index (RSI) of 46.90. Get the full research report on ACAD for free by clicking below at: www.wallstequities.com/registration/?symbol=ACAD
On Friday, shares in South San Francisco, California-based Achaogen Inc. ended the session 3.63% lower at $10.74. The stock recorded a trading volume of 1.15 million shares, which was higher than its three months average volume of 1.13 million shares. The Company's shares have gained 1.32% in the last month. The stock is trading 5.13% below its 50-day moving average. Moreover, shares of Achaogen, which discovers, develops, and commercializes antibacterials to treat multi-drug resistant gram-negative infections in the US, have an RSI of 44.82.
On January 25th, 2018, Achaogen announced that on January 19th, 2018, the compensation committee of its Board of Directors granted six new employees the option to purchase an aggregate of 30,000 shares of the Company's common stock and 15,001 restricted stock units. Each stock option has an exercise price per share equal to $11.54, which was the closing trading price on January 19th, 2018. Access the free research report on AKAO now by signing up at: www.wallstequities.com/registration/?symbol=AKAO
New Haven, Connecticut headquartered Achillion Pharmaceuticals Inc.'s shares declined 1.47%, closing the session at $2.68 with a total trading volume of 1.33 million shares. The stock is trading 10.21% below its 50-day moving average. Shares of the Company, which discovers, develops, and commercializes small molecule drug therapies for infectious diseases and immune system disorders in the US and internationally, have an RSI of 33.84. Are you already registered with Wall St. Equities? Do so now for free, and get the report on ACHN at: www.wallstequities.com/registration/?symbol=ACHN
Last Friday at the close, shares in Ardsley, New York headquartered Acorda Therapeutics Inc. recorded a trading volume of 427,928 shares. The stock ended the session 3.62% lower at $25.30. The Company's shares have advanced 15.53% in the past month and 19.91% over the past year. The stock is trading above its 50-day and 200-day moving averages by 10.97% and 18.14%, respectively. Furthermore, shares of Acorda Therapeutics, which identifies, develops, and commercializes therapies for neurological disorders in the US, have an RSI of 51.75.
On January 17th, 2018, research firm H.C. Wainwright reiterated its 'Buy' rating on the Company's stock with a decrease of the target price from $34 a share to $31 a share.
On February 02nd, 2018, Acorda Therapeutics announced that it will host a conference call and webcast on February 15th, 2018, at 8:30 a.m. ET to report its Q4 2017 financial results and pipeline updates. The presentation will be available under the Investors section of the Company's website. Aspiring Member, please take a moment to register below for your free research report on ACOR at: www.wallstequities.com/registration/?symbol=ACOR
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:Email: firstname.lastname@example.org Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/technical-perspectives-on-biotech-stocks----acadia-pharma-achaogen-achillion-pharma-and-acorda-therapeutics-300593257.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!
Collagen plays a crucial role in glowing skin, strong nails and shiny hair. You can boost collagen ...
CRISPR technology is a simple but potent tool for editing any part of the genome (complete set of ...
FDA recently approved Mogamulizumab-kpkc, a human monoclonal antibody prescribed for adult ...View All